MedTrace Logo

Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events

NCT00886574 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2010-06-04

No results posted yet for this study

Summary

This multi-center, randomized controlled study aims to evaluate the efficacy of Cilostazol versus Aspirin for primary prevention of atherosclerotic events with Korean type 2 Diabetes Mellitus (DM) patients.

Conditions

Interventions

DRUG

Cilostazol

Cilostazol 200 mg (50 mg 2T twice per day)

DRUG

Aspirin

100 mg once a day

Sponsors & Collaborators

  • Ajou University School of Medicine

    collaborator OTHER

  • Kyunghee University Medical Center

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • Inha University Hospital

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • Hallym University Medical Center

    collaborator OTHER

  • Hanyang University

    lead OTHER

Principal Investigators

  • Yongsoo Park, M.D. Ph.D · Department of Internal Medicine, Hanyang University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-02-28
Completion
2014-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886574 on ClinicalTrials.gov